EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudiePragmatische StudieOpen Access · CC BY-NC 4.0

Associations of methadone and buprenorphine‐naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription‐type opioid use disorders: Exploratory analyses of the OPTIMA study

Hamzah Bakouni, Christina McAnulty, Ovidiu Tatar iD, M Eugenia Socias, Bernard Le Foll, Ron Lim, Keith Ahamad, Didier Jutras-Aswad iD, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse

The American Journal on Addictions · 2023

DOI: 10.1111/ajad.13439 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The American Journal on Addictions, 2023. Verfasst von Hamzah Bakouni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Quebec, Montréal, Canada. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Buprenorphine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Buprenorphine/naloxone (BUP‐NX) and methadone are used to treat opioid use disorder (OUD), yet there is insufficient evidence on the impact of doses on interventions' effectiveness and safety when treating OUD attributable to other opioids than heroin.

Methods

We explored associations between methadone and BUP‐NX doses and treatment outcomes using data from OPTIMA, a 24‐week, pragmatic, open‐label, multicenter, pan‐Canadian, randomized controlled, two‐arm parallel trial with participants ( N = 272) with OUD who primarily use opioids other than heroin. Participants were randomized to receive flexible take‐home BUP‐NX ( n = 138) or standard supervised methadone treatment ( n = 134). We examined associations between highest BUP‐NX and methadone doses, and (1) percentage of opioid‐positive urine drug screens (UDS); (2) retention in the assigned treatment; and (3) adverse events (AEs).

Results

The mean (SD) highest BUP‐NX and methadone dose were 17.31 mg/day (8.59) and 67.70 mg/day (34.70). BUP‐NX and methadone doses were not associated with opioid‐positive UDS percentages or AEs. Methadone dose was associated with higher retention in treatment (odds ratio [OR]: 1.025; 95% confidence interval [CI]: 1.010; 1.041), while BUP‐NX dose was not (OR: 1.055; 95% CI: 0.990; 1.124). Higher methadone doses (70–110 mg/day) offered higher odds of treatment retention. Discussion and Conclusion Methadone dose was associated with higher retention, which may be related to its full µ‐opioid receptor agonism. Future research should notably ascertain the effect of pace of titration on a wide range of outcomes. Scientific Significance Our results extend previous findings of high doses of methadone increasing retention to be applied in our population using opioids other than heroin, including highly potent opioids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersBuprenorphineHumansBuprenorphine, Naloxone Drug CombinationMethadoneAnalgesics, OpioidHeroinOpiate Substitution TreatmentCanadaPrescriptionsNarcotic Antagonists

Substanzen

Buprenorphine, Naloxone Drug CombinationMethadoneAnalgesics, OpioidHeroinBuprenorphineNarcotic Antagonists

Autor:innen und Institutionen

  • Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Quebec, Montréal, Canada.
  • Department of Psychiatry and Addictology, Université de Montréal, Québec, Montréal, Canada.
  • British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
  • Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Department of Pharmacology and Toxicology, Faculty of Medicine, Medical Sciences Building, University of Toronto, Ontario, Toronto, Canada.
  • Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Ontario, Toronto, Canada.

ORCID-Profile: Ovidiu Tatar, Didier Jutras-Aswad

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Bakouni, H., McAnulty, C., Tatar, O., Socias, M. E., Le Foll, B., Lim, R., Ahamad, K., Jutras-Aswad, D., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2023). Associations of methadone and buprenorphine‐naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription‐type opioid use disorders: Exploratory analyses of the OPTIMA study. The American Journal on Addictions. https://doi.org/10.1111/ajad.13439

Vancouver

Bakouni H, McAnulty C, Tatar O, Socias ME, Le Foll B, Lim R, et al. Associations of methadone and buprenorphine‐naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription‐type opioid use disorders: Exploratory analyses of the OPTIMA study. The American Journal on Addictions. 2023. doi:10.1111/ajad.13439

BibTeX
@article{Bakouni2023,
  author = {Bakouni, Hamzah and McAnulty, Christina and Tatar, Ovidiu and Socias, M Eugenia and Le Foll, Bernard and Lim, Ron and Ahamad, Keith and Jutras-Aswad, Didier and OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse},
  title = {Associations of methadone and buprenorphine‐naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription‐type opioid use disorders: Exploratory analyses of the OPTIMA study},
  journal = {The American Journal on Addictions},
  year = {2023},
  doi = {10.1111/ajad.13439}
}
Kostenlos starten →